Pomalidomide+Dexamethasone (Pd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3,>=4 prior line of therapy, Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, Anti-CD38 MAb, Lenalidomide Exposed
### Instruction:
Identify the study with the following condition. 
### Input:
Pomalidomide+Dexamethasone (Pd), Relapsed Refractory Multiple Myeloma (RRMM), 1,2,3,>=4 prior line of therapy, Daratumumab+Pomalidomide+Dexamethasone (DPd), Phase 3, Anti-CD38 MAb, Lenalidomide Exposed 
### Output:
Popular Name is APOLLO, Study ID is NCT03180736